COVID-19Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects
Graphical abstract
Key words
SARS-CoV-2
SARS-CoV-2 vaccination
primary immunodeficiency
ACE2 blocking antibody
SARS-CoV-2 spike protein antibody
antibody deficiency
common variable immunodeficiency
Good syndrome
mAb
SARS-CoV-2 IFN-γ release assay
Abbreviations used
ACE2
Angiotensin-converting enzyme 2
COVID-19
Coronavirus disease 2019
CTLA-4
Cytotoxic T lymphocyte–associated protein 4
CVID
Common variable immunodeficiency
ELISA
Enzyme-linked immunosorbent assay
EUA
Emergency use authorization
IGRA
IFN-γ release assay
IVIG
Intravenous immunoglobulin
mRNA
Messenger RNA
PID
primary immunodeficiency
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Cited by (0)
The last 2 authors contributed equally to this article, and both should be considered senior author.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
© 2021 American Academy of Allergy, Asthma & Immunology